Company intelligence / Profile preview
Magellan Stem Cells
Sydney, New South Wales, Australia
- Ownership
- Private
- Development stage
- Other
01
Overview
Magellan has completed Phase I/II allogeneic osteoarthritis trials (2023–2024), with pivotal Phase III trial planned to start in 2025 aimed at demonstrating efficacy and safety for MAG200 in osteoarthritis. Preclinical and earlier clinical data support the use of MSCs to improve pain and mobility in osteoarthritis; full data have not yet been published.
- Therapeutic areas
- Rheumatology
- Modalities
- Cell therapyMesenchymal stem cell therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Not publicly disclosed (company self-funded, with capital raises in 2012, 2022, 2023, 2024, and 2025)
Beyond the preview
Go deeper on Magellan Stem Cells.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Magellan Stem Cells.